Act-Hib is a vaccine used to prevent purulent-septic diseases caused by Haemophilus influenzae type b. The drug does not contain living microorganisms, making it impossible to get sick as a result of the injection.
Release form and composition
The drug is available in the form of a lyophilisate for preparing a solution for subcutaneous and intramuscular administration. One dose contains 10 µg of tetanus toxoid. A 4% sodium chloride solution is used as a solvent.
Indications for use Act Hiba
The drug Act-Hib is used to prevent purulent-septic diseases (CIB infections): meningitis, arthritis, sepsis, pneumonia, epiglottitis. It is permissible to apply the Act-Hib in children from three months of age.
The instructions to the Act-Hibu indicated the following contraindications:
- Allergy to vaccine ingredients;
- Exacerbation of chronic diseases;
- Acute diseases.
Vaccinations are given 2-4 weeks after recovery. In the case of a mild form of intestinal or respiratory infection, vaccination can be carried out immediately after the body temperature returns to normal.
Dosage and Administration Act Hiba
The vaccine is injected deep subcutaneously or intramuscularly. Single dose of the drug - 0.5 ml. Before administering the vaccine, make sure that the needle touches the blood vessel.
Children older than 2 years of age, the vaccine is injected into the region of the deltoid muscle, and children under 2 years old - in the middle third of the anterolateral thigh.
The duration of the vaccination course depends on the age of the child. If vaccination starts at the age of 1 to 5 years, a single injection is sufficient. At the beginning of vaccination at the age from six months to a year: 2 injections with an interval of 1 month. Revaccination is carried out once at the age of 18 months. The use of Act-Hiba in children under six months implies 3 injections with an interval of 1-2 months. Revaccination is carried out once a year after the third injection.
Side effects Act-Hiba
According to the instructions to the Act-Hibu, the following side effects from the use of the drug are possible:
- Local reactions - soreness, swelling, inflammation, erythema, irritation, induration at the injection site;
- Prolonged crying, fever;
- In some cases, peripheral edema of the lower extremities;
- Hypersensitivity reactions: cramps, rash, urticaria, and itching.
The drug does not form an immunity against meningitis of a different ecology and infections caused by other serotypes of Haemophilus influenzae. The tetanus protein, which is part of the Act-Hiba, can not replace vaccination against tetanus.
In children younger than 4 months, isolated cases of peripheral edema of the lower extremities were noted after the injection of the vaccine with the CIB component. More than 50% of cases occurred within six hours. Similar reactions developed with the introduction of combined vaccines (against tetanus, whooping cough, diphtheria).
The edema spread to both lower limbs, or only to one, in the first case, the edema prevailed on the limb where the vaccine was introduced. This reaction may be accompanied by fever, soreness, shrill crying, rash, and discoloration of the skin. Such cases took place without residual effects, within 24 hours after the injection, and did not lead to adverse events on the part of the respiratory system and the heart.
Analogs of Act Hiba
The analogue of the drug Act-Hib is Hiberiks, also available in powder form for the preparation of a solution for subcutaneous and intramuscular administration.
Terms and conditions of storage
The drug Act-Hib should be stored at 2-8 ° C (in the refrigerator), out of the reach of children. Do not freeze. Shelf life is 3 years.